Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 4/2011

01-12-2011 | Original Article

Warfarin anticoagulation: a survey of patients’ knowledge of their treatment

Authors: S. M. Moran, N. Fitzgerald, M. Pope, M. Madden, C. J. Vaughan

Published in: Irish Journal of Medical Science (1971 -) | Issue 4/2011

Login to get access

Abstract

Introduction

Warfarin is used for the treatment of thromboembolic disease. It requires careful and sustained monitoring due to its narrow therapeutic index and potentially life-threatening complications. Patient education and knowledge is, therefore, vital.

Aims

To assess, in a specialised anticoagulation clinic, the extent of patients’ knowledge of their warfarin treatment.

Methods

Ethical approval was obtained. All patients, aged over 18 years, attending our anticoagulation clinic during our study period were asked to participate.

Results

We enrolled 181 patients, 47.9% of respondents were unaware of any potential drug interactions, 57.7% of patients were unaware of any potential side effects, 20% of patients had experienced side effects, 10.9% of patients had been hospitalised due to side effects, 58% of which were due to Haemorrhage and 79% of patients kept a personal record of their INR.

Conclusions

Patients’ understanding of warfarin treatment was poor, despite their high level of compliance.
Literature
1.
go back to reference Hirsch J, Fuster V, Ansell J et al (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41(9):1633–1652 Hirsch J, Fuster V, Ansell J et al (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41(9):1633–1652
2.
3.
go back to reference Summary of Product Characteristics. PA 73/139/1 Warfarin, Irish Medicines Board. www.imb.ie Accessed on 19 Dec 2005 Summary of Product Characteristics. PA 73/139/1 Warfarin, Irish Medicines Board. www.​imb.​ie Accessed on 19 Dec 2005
5.
go back to reference Saour JN, Sieck JO, Mamo LAR et al (1990). Trial of different intensities of anticoagulation in patients with prosthetic heart valves. NEJM 322(7):428–432 Saour JN, Sieck JO, Mamo LAR et al (1990). Trial of different intensities of anticoagulation in patients with prosthetic heart valves. NEJM 322(7):428–432
6.
go back to reference Drug Interactions with coumarin derivative anticoagulants (1982) Standing advisory committee for haematology of the royal college of pathologists. BMJ 285(6337):274–275CrossRef Drug Interactions with coumarin derivative anticoagulants (1982) Standing advisory committee for haematology of the royal college of pathologists. BMJ 285(6337):274–275CrossRef
7.
go back to reference Tang EO, Lai CS, Lee KK et al (2003) Relationship between patients’ warfarin knowledge and anticoagulation control. Ann Pharmacother 37(1):34–39PubMedCrossRef Tang EO, Lai CS, Lee KK et al (2003) Relationship between patients’ warfarin knowledge and anticoagulation control. Ann Pharmacother 37(1):34–39PubMedCrossRef
8.
go back to reference Hu A, Chow CM, Dao D, Errett L, Keith Ml (2006) Factors influencing patient knowledge of warfarin therapy after mechanical heart valve replacement. J Cardiovasc Nurs 21(3):169–175PubMed Hu A, Chow CM, Dao D, Errett L, Keith Ml (2006) Factors influencing patient knowledge of warfarin therapy after mechanical heart valve replacement. J Cardiovasc Nurs 21(3):169–175PubMed
9.
go back to reference Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors know at the start of outpatient therapy. Am J Med 87(2):144–152PubMedCrossRef Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors know at the start of outpatient therapy. Am J Med 87(2):144–152PubMedCrossRef
12.
go back to reference Gurwitz JH, Field TS, Harrold LR et al (2003) Incidence and Preventability of Adverse Drug Events among Older Persons in the Ambulatory Setting, JAMA 289(9):1107–1116. Gurwitz JH, Field TS, Harrold LR et al (2003) Incidence and Preventability of Adverse Drug Events among Older Persons in the Ambulatory Setting, JAMA 289(9):1107–1116.
13.
go back to reference Budnitz DS, Pollock DA, Weidenbach KN et al (2006) National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296(15):1858–1866. Budnitz DS, Pollock DA, Weidenbach KN et al (2006) National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296(15):1858–1866.
14.
go back to reference Njasstad AM, Abildgaard U, Lassen JF (2006) Gains and losses of warfarin therapy as performed in an anticoagulation clinic. J Intern Med 259(3):296–304CrossRef Njasstad AM, Abildgaard U, Lassen JF (2006) Gains and losses of warfarin therapy as performed in an anticoagulation clinic. J Intern Med 259(3):296–304CrossRef
15.
go back to reference Kumar S, Haigh JRM, Rhodes LE, Peaker S, Davies JA, Roberts BE, Feely MPl (1989) Poor compliance is a major risk factor in unstable outpatient control of anticoagulation therapy. J Thromb Haemost 62(2):729–732 Kumar S, Haigh JRM, Rhodes LE, Peaker S, Davies JA, Roberts BE, Feely MPl (1989) Poor compliance is a major risk factor in unstable outpatient control of anticoagulation therapy. J Thromb Haemost 62(2):729–732
Metadata
Title
Warfarin anticoagulation: a survey of patients’ knowledge of their treatment
Authors
S. M. Moran
N. Fitzgerald
M. Pope
M. Madden
C. J. Vaughan
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Irish Journal of Medical Science (1971 -) / Issue 4/2011
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-011-0726-0

Other articles of this Issue 4/2011

Irish Journal of Medical Science (1971 -) 4/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.